Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CT-0508,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Carisma Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Carisma Therapeutics Closes Merger with Sesen Bio
Details : The combined company will develop Carisma's lead candidate CT-0508, a CAR-M cell therapy and will also accelerate the growth of company's platform and pipeline within and outside of oncology.
Product Name : CT-0508
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 21, 2023
Lead Product(s) : CT-0508,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Carisma Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : CT-0508
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Carisma Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
Details : The first clinical application of this technology is CT-0508, a CAR-M cell therapy currently being evaluated by Carisma in a Phase 1 multi-center clinical trial with a lead target indication of advanced HER2+ solid tumors.
Product Name : CT-0508
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 21, 2022
Lead Product(s) : CT-0508
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Carisma Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US
Details : VB4-845 (vicineum), a locally administered fusion protein for treatment of NMIBC, is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule antigens on surface of tumor cells to deliver a potent protein payload, Pseudomo...
Product Name : VB4-845
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
July 18, 2022
Sesen Bio Expands CMC and Clinical Teams
Details : Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A.
Product Name : Vicineum
Product Type : Protein
Upfront Cash : Inapplicable
October 12, 2021
Sesen Bio Receives Complete Response Letter from FDA for Vicineum™ (oportuzumab monatox-qqrs)
Details : Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A.
Product Name : Vicineum
Product Type : Protein
Upfront Cash : Inapplicable
August 13, 2021
Sesen Bio Approaches the Potential Approval and Commercial Launch of Vicineum™
Details : Vicineum is comprised of a recombinant fusion protein that targets EpCAM antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A. It is currently under Priority Review with the FDA with a target PDUFA date of Au...
Product Name : Vicineum
Product Type : Protein
Upfront Cash : Inapplicable
August 11, 2021
Details : Vicineum is constructed with a stable, genetically engineered peptide tether to ensure the payload remains attached to the antibody binding fragment until it is internalized by the cancer cell.
Product Name : Vicineum
Product Type : Protein
Upfront Cash : Inapplicable
August 02, 2021
Details : Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC).
Product Name : Vicineum
Product Type : Protein
Upfront Cash : Inapplicable
February 16, 2021
Details : Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC). The BLA is supported by strong Phase 3 VISTA trial data and positive analy...
Product Name : VB4-845
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
December 21, 2020
Details : EMA addressed product-specific, legal, regulatory and scientific topics related to Vicineum. The information and insights gained from the meeting will help to facilitate the validation of the Marketing Authorization Application (“MAA”) and support a ...
Product Name : VB4-845
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
October 26, 2020
Reset All
